Stocks / NASDAQ / Poseida Therapeutics Inc.

Poseida Therapeutics Inc.

Our Opinion

Poseida Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

The company stated in the following report that they exploit animals for product testing.

“P-PSMA-101 resulted in the elimination of tumor cells to undetectable levels in 100% of animals in a preclinical model of prostate cancer. To our knowledge based on published literature, no other product candidate has shown complete solid tumor elimination in any animal in this same preclinical model.” (Page 2) Read the full document

Company Description

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The company was incorporated in 2014 and is headquartered in San Diego, California.

Company Website: